article thumbnail

Um, about that diabetes drug that helped patients lose weight

World of DTC Marketing

Wegovy’s most common side effects were gastrointestinal problems, including nausea, diarrhea, and vomiting, which 80% of patients reported, according to USA Today. Novo’s PR department did a great job and most articles about the drug did talk about the side effects but how many people really read that deep?

article thumbnail

Thursday pharma headlines

World of DTC Marketing

million, his first big raise since 2015, thanks to incentive pay that jumped by about $1.2 million in 2020, more than double the number in 2015, according to health data company IQVIA. Food and Drug Administration (FDA) is meant to help patients and warn of potential drug side effects but a Vice report indicates something more.

Pharma 180
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Value-Based healthcare won’t work

World of DTC Marketing

There are many reasons why people don’t take their medications, including cost and medication side effects but that’s only part of the picture. Medicatio n adherence can hav e a more direct impact on patient outcomes than the specific treatment. Americans are not healthy.

article thumbnail

Clinical trials authorised for 3D-printed ulcerative colitis drug

European Pharmaceutical Review

. “Delaying drug release and delivering oral dosage forms to the colon is challenging, so T21 offers a promising new option for ulcerative colitis patients by providing site-specific drug delivery and localised drug effect, mitigating potential side effects from systemic exposure.

article thumbnail

The end-of-life care conundrum

pharmaphorum

The study that emerged from scientists at the Yale Cancer Center, working in collaboration with researchers from Flatiron Health, concluded that there is no difference between the overall use of systemic anti-cancer therapy at the end-of-life stage since 2015.

article thumbnail

FDA rejects Spectrum’s lung cancer drug poziotinib

pharmaphorum

The phase 2 ZENITH20 study showed an objective response rate (ORR) of 28% with a median duration of response of around five months, and 12% of patients had to discontinue therapy due to side effects. Spectrum licensed worldwide rights to poziotinib – excluding Korea and China – from Hanmi in back in 2015.

FDA 98
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

This is especially beneficial as a way of decreasing potential side effects. In the years 2015 and 2020, clinical-stage cancer programmes increased by a considerable 77 percent (1,642 to 2,911), resulting in a quarter of drugs currently in development worldwide being highly potent.